Introduction {#s1}
============

Diagnostic accuracy studies are at risk of bias, not unlike other clinical studies. Major sources of bias originate in methodological deficiencies, in participant recruitment, data collection, executing or interpreting the test or in data analysis.[@R1] [@R2] As a result, the estimates of sensitivity and specificity of the test that is compared against the reference standard can be flawed, deviating systematically from what would be obtained in ideal circumstances (see key terminology in [table 1](#BMJOPEN2016012799TB1){ref-type="table"}). Biased results can lead to improper recommendations about testing, negatively affecting patient outcomes or healthcare policy.

###### 

Key STARD terminology

  Term                          Explanation
  ----------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------
  Medical test                  Any method for collecting additional information about the current or future health status of a patient
  Index test                    The test under evaluation
  Target condition              The disease or condition that the index test is expected to detect
  Clinical reference standard   The best available method for establishing the presence or absence of the target condition. A gold standard would be an error-free reference standard
  Sensitivity                   Proportion of those with the target condition who test positive with the index test
  Specificity                   Proportion of those without the target condition who test negative with the index test
  Intended use of the test      Whether the index test is used for diagnosis, screening, staging, monitoring, surveillance, prediction, prognosis or other reasons
  Role of the test              The position of the index test relative to other tests for the same condition (eg, triage, replacement, add-on, new test)
  Indeterminate results         Results that are neither positive or negative

Diagnostic accuracy is not a fixed property of a test. A test\'s accuracy in identifying patients with the target condition typically varies between settings, patient groups and depending on prior testing.[@R2] These sources of variation in diagnostic accuracy are relevant for those who want to apply the findings of a diagnostic accuracy study to answer a specific question about adopting the test in his or her environment. Risk of bias and concerns about the applicability are the two key components of QUADAS-2, a quality assessment tool for diagnostic accuracy studies.[@R3]

Readers can only judge the risk of bias and applicability of a diagnostic accuracy study if they find the necessary information to do so in the study report. The published study report has to contain all the essential information to judge the trustworthiness and relevance of the study findings, in addition to a complete and informative disclose about the study results.

Unfortunately, several surveys have shown that diagnostic accuracy study reports often fail to transparently describe core elements.[@R4] Essential information about included patients, study design and the actual results is frequently missing, and recommendations about the test under evaluation are often generous and too optimistic.

To facilitate more complete and transparent reporting of diagnostic accuracy studies, the STARD statement was developed: Standards for Reporting of Diagnostic Accuracy Studies.[@R7] Inspired by the Consolidated Standards for the Reporting of Trials or CONSORT statement for reporting randomised controlled trials,[@R8] [@R9] STARD contains a checklist of items that should be reported in any diagnostic accuracy study.

The STARD statement was initially released in 2003 and updated in 2015.[@R10] The objectives of this update were to include recent evidence about sources of bias and variability and other issues in complete reporting, and make the STARD list easier to use. The updated STARD 2015 list now has 30 essential items ([table 2](#BMJOPEN2016012799TB2){ref-type="table"}).

###### 

The STARD 2015 list[@R10]

  Section and topic       No    Item
  ----------------------- ----- -------------------------------------------------------------------------------------------------------------------------------------------------------
  **Title or abstract**         
                          1     Identification as a study of diagnostic accuracy using at least one measure of accuracy (such as sensitivity, specificity, predictive values or AUC)
  **Abstract**                  
                          2     Structured summary of study design, methods, results and conclusions (for specific guidance, see STARD for Abstracts)
  **Introduction**              
                          3     Scientific and clinical background, including the intended use and clinical role of the index test
                          4     Study objectives and hypotheses
  **Methods**                   
  Study design            5     Whether data collection was planned before the index test and reference standard were performed (prospective study) or after (retrospective study)
  Participants            6     Eligibility criteria
                          7     On what basis potentially eligible participants were identified (such as symptoms, results from previous tests, inclusion in registry)
                          8     Where and when potentially eligible participants were identified (setting, location and dates)
                          9     Whether participants formed a consecutive, random or convenience series
  Test methods            10a   Index test, in sufficient detail to allow replication
                          10b   Reference standard, in sufficient detail to allow replication
                          11    Rationale for choosing the reference standard (if alternatives exist)
                          12a   Definition of and rationale for test positivity cut-offs or result categories of the index test, distinguishing prespecified from exploratory
                          12b   Definition of and rationale for test positivity cut-offs or result categories of the reference standard, distinguishing prespecified from exploratory
                          13a   Whether clinical information and reference standard results were available to the performers or readers of the index test
                          13b   Whether clinical information and index test results were available to the assessors of the reference standard
  Analysis                14    Methods for estimating or comparing measures of diagnostic accuracy
                          15    How indeterminate index test or reference standard results were handled
                          16    How missing data on the index test and reference standard were handled
                          17    Any analyses of variability in diagnostic accuracy, distinguishing prespecified from exploratory
                          18    Intended sample size and how it was determined
  **Results**                   
  Participants            19    Flow of participants, using a diagram
                          20    Baseline demographic and clinical characteristics of participants
                          21a   Distribution of severity of disease in those with the target condition
                          21b   Distribution of alternative diagnoses in those without the target condition
                          22    Time interval and any clinical interventions between index test and reference standard
  Test results            23    Cross tabulation of the index test results (or their distribution) by the results of the reference standard
                          24    Estimates of diagnostic accuracy and their precision (such as 95% CIs)
                          25    Any adverse events from performing the index test or the reference standard
  **Discussion**                
                          26    Study limitations, including sources of potential bias, statistical uncertainty and generalisability
                          27    Implications for practice, including the intended use and clinical role of the index test
  **Other information**         
                          28    Registration number and name of registry
                          29    Where the full study protocol can be accessed
                          30    Sources of funding and other support; role of funders

Below, we present an explanation and elaboration of STARD 2015. This is an extensive revision and update of a similar document that was prepared for the STARD 2003 version.[@R11] Through commented examples of appropriate reporting, we clarify the rationale for each item and describe what is expected from authors.

We are confident that these descriptions can further assist scientists in writing fully informative study reports, and help peer reviewers, editors and other readers in verifying that submitted and published manuscripts of diagnostic accuracy studies are sufficiently detailed.

STARD 2015 items: explanation and elaboration {#s2}
=============================================

Title or abstract {#s2a}
-----------------

Item 1. Identification as a study of diagnostic accuracy using at least one measure of accuracy (such as sensitivity, specificity, predictive values or AUC)

**Example**. 'Main outcome measures: Sensitivity and specificity of CT colonography in detecting individuals with advanced neoplasia (i.e., advanced adenoma or colorectal cancer) 6 mm or larger'.[@R12]

**Explanation**. When searching for relevant biomedical studies on a certain topic, electronic databases such as MEDLINE and Embase are indispensable. To facilitate retrieval of their article, authors can explicitly identify it as a report of a diagnostic accuracy study. This can be performed by using terms in the title and/or abstract that refer to measures of diagnostic accuracy, such as 'sensitivity', 'specificity', 'positive predictive value', 'negative predictive value', 'area under the ROC curve (AUC)' or 'likelihood ratio'.

In 1991, MEDLINE introduced a specific keyword (MeSH heading) for indexing diagnostic studies: 'Sensitivity and Specificity.' Unfortunately, the sensitivity of using this particular MeSH heading to identify diagnostic accuracy studies can be as low as 51%.[@R13] As of May 2015, Embase\'s thesaurus (Emtree) has 38 check tags for study types; 'diagnostic test accuracy study' is one of them, but was only introduced in 2011.

*In the example*, the authors mentioned the terms 'sensitivity' and 'specificity' in the abstract. The article will now be retrieved when using one of these terms in a search strategy, and will be easily identifiable as one describing a diagnostic accuracy study.

Abstract {#s2b}
--------

Item 2. Structured summary of study design, methods, results and conclusions (for specific guidance, see STARD for Abstracts)

**Example**. See STARD for Abstracts (*manuscript in preparation; checklist will be available at* <http://www.equator-network.org/reporting-guidelines/stard/>).

**Explanation**. Readers use abstracts to decide whether they should retrieve the full study report and invest time in reading it. In cases where access to the full study report cannot be obtained or where time is limited, it is conceivable that clinical decisions are based on the information provided in abstracts only.

In two recent literature surveys, abstracts of diagnostic accuracy studies published in high-impact journals or presented at an international scientific conference were found insufficiently informative, because key information about the research question, study methods, study results and the implications of findings were frequently missing.[@R14] [@R15]

Informative abstracts help readers to quickly appraise critical elements of study validity (risk of bias) and applicability of study findings to their clinical setting (generalisability). Structured abstracts, with separate headings for objectives, methods, results and interpretation, allow readers to find essential information more easily.[@R16]

Building on STARD 2015, the newly developed STARD for Abstracts provides a list of essential items that should be included in journal and conference abstracts of diagnostic accuracy studies *(list finalised; manuscript under development)*.

Introduction {#s2c}
------------

Item 3. Scientific and clinical background, including the intended use and clinical role of the index test

**Example**. 'The need for improved efficiency in the use of emergency department radiography has long been documented. This need for selectivity has been identified clearly for patients with acute ankle injury, who generally are all referred for radiography, despite a yield for fracture of less than 15%. The referral patterns and yield of radiography for patients with knee injuries have been less well described but may be more inefficient than for patients with ankle injuries. \[...\] The sheer volume of low-cost tests such as plain radiography may contribute as much to rising health care costs as do high-technology, low-volume procedures. \[...\] If validated in subsequent studies, a decision rule for knee-injury patients could lead to a large reduction in the use of knee radiography and significant health care savings without compromising patient care'.[@R17]

**Explanation**. In the introduction of scientific study reports, authors should describe the rationale for their study. In doing so, they can refer to previous work on the topic, remaining uncertainty and the clinical implications of this knowledge gap. To help readers in evaluating the implications of the study, authors can clarify the intended use and the clinical role of the test under evaluation, which is referred to as the index test.

The intended use of a test can be diagnosis, screening, staging, monitoring, surveillance, prognosis, treatment selection or other purposes.[@R18] The clinical role of the test under evaluation refers to its anticipated position relative to other tests in the clinical pathway.[@R19] A triage test, for example, will be used before an existing test because it is less costly or burdensome, but often less accurate as well. An add-on test will be used after existing tests, to improve the accuracy of the total test strategy by identifying false positives or false negatives of the initial test. In other cases, a new test may be used to replace an existing test.

Defining the intended use and clinical role of the test will guide the design of the study and the targeted level of sensitivity and specificity; from these definitions follow the eligibility criteria, how and where to identify eligible participants, how to perform tests and how to interpret test results.[@R19]

Specifying the clinical role is helpful in assessing the relative importance of potential errors (false positives and false negatives) made by the index test. A triage test to rule out disease, for example, will need very high sensitivity, whereas the one that mainly aims to rule in disease will need very high specificity.

*In the example*, the intended use is diagnosis of knee fractures in patients with acute knee injuries, and the potential clinical role is triage test; radiography, the existing test, would only be performed in those with a positive outcome of the newly developed decision rule. The authors outline the current scientific and clinical background of the health problem studied, and their reason for aiming to develop a triage test: this would reduce the number of radiographs and, consequently, healthcare costs.

Item 4. Study objectives and hypotheses

**Example (1)**. 'The objective of this study was to evaluate the sensitivity and specificity of 3 different diagnostic strategies: a single rapid antigen test, a rapid antigen test with a follow-up rapid antigen test if negative (rapid-rapid diagnostic strategy), and a rapid antigen test with follow-up culture if negative (rapid-culture)---the AAP diagnostic strategy---all compared with a 2-plate culture gold standard. In addition, \[...\] we also compared the ability of these strategies to achieve an absolute diagnostic test sensitivity of \>95%'.[@R20]

**Example (2)**. 'Our 2 main hypotheses were that rapid antigen detection tests performed in physician office laboratories are more sensitive than blood agar plate cultures performed and interpreted in physician office laboratories, when each test is compared with a simultaneous blood agar plate culture processed and interpreted in a hospital laboratory, and rapid antigen detection test sensitivity is subject to spectrum bias'.[@R21]

**Explanation**. Clinical studies may have a general aim (a long-term goal, such as 'to improve the staging of oesophageal cancer'), specific objectives (well-defined goals for this particular study) and testable hypotheses (statements than can be falsified by the study results).

In diagnostic accuracy studies, statistical hypotheses are typically defined in terms of acceptability criteria for single tests (minimum levels of sensitivity, specificity or other measures). In those cases, hypotheses generally include a quantitative expression of the expected value of the diagnostic parameter. In other cases, statistical hypotheses are defined in terms of equality or non-inferiority in accuracy when comparing two or more index tests.

A priori specification of the study hypotheses limits the chances of post hoc data-dredging with spurious findings, premature conclusions about the performance of tests or subjective judgement about the accuracy of the test. Objectives and hypotheses also guide sample size calculations. An evaluation of 126 reports of diagnostic test accuracy studies published in high-impact journals in 2010 revealed that 88% did not state a clear hypothesis.[@R22]

*In the first example*, the authors\' objective was to evaluate the accuracy of three diagnostic strategies; their specific hypothesis was that the sensitivity of any of these would exceed the prespecified value of 95%. *In the second example*, the authors explicitly describe the hypotheses they want to explore in their study. The first hypothesis is about the comparative sensitivity of two index tests (rapid antigen detection test vs culture performed in physician office laboratories); the second is about variability of rapid test performance according to patient characteristics (spectrum bias).

Methods {#s2d}
-------

Item 5. Whether data collection was planned before the index test and reference standard were performed (prospective study) or after (retrospective study)

**Example**. 'We reviewed our database of patients who underwent needle localization and surgical excision with digital breast tomosynthesis guidance from April 2011 through January 2013. \[...\] The patients' medical records and images of the 36 identified lesions were then reviewed retrospectively by an author with more than 5 years of breast imaging experience after a breast imaging fellowship'.[@R23]

**Explanation**. There is great variability in the way the terms 'prospective' and 'retrospective' are defined and used in the literature. We believe it is therefore necessary to describe clearly whether data collection was planned before the index test and reference standard were performed, or afterwards. If authors define the study question before index test and reference standards are performed, they can take appropriate actions for optimising procedures according to the study protocol and for dedicated data collection.[@R24]

Sometimes, the idea for a study originates when patients have already undergone the index test and the reference standard. If so, data collection relies on reviewing patient charts or extracting data from registries. Though such retrospective studies can sometimes reflect routine clinical practice better than prospective studies, they may fail to identify all eligible patients, and often result in data of lower quality, with more missing data points.[@R24] A reason for this could be, for example, that in daily clinical practice, not all patients undergoing the index test may proceed to have the reference standard.

*In the example*, the data were clearly collected retrospectively: participants were identified through database screening, clinical data were abstracted from patients\' medical records, though images were reinterpreted.

Item 6. Eligibility criteria

**Example (1).** 'Patients eligible for inclusion were consecutive adults (≥18 years) with suspected pulmonary embolism, based on the presence of at least one of the following symptoms: unexplained (sudden) dyspnoea, deterioration of existing dyspnoea, pain on inspiration, or unexplained cough. We excluded patients if they received anticoagulant treatment (vitamin K antagonists or heparin) at presentation, they were pregnant, follow-up was not possible, or they were unwilling or unable to provide written informed consent'.[@R25]

**Example (2)**. 'Eligible cases had symptoms of diarrhoea and both a positive result for toxin by enzyme immunoassay and a toxigenic *C difficile* strain detected by culture (in a sample taken less than seven days before the detection round). We defined diarrhoea as three or more loose or watery stool passages a day. We excluded children and adults on intensive care units or haematology wards. Patients with a first relapse after completing treatment for a previous *C difficile* infection were eligible but not those with subsequent relapses. \[...\] For each case we approached nine control patients. These patients were on the same ward as and in close proximity to the index patient. Control patients did not have diarrhoea, or had diarrhoea but a negative result for *C difficile* toxin by enzyme immunoassay and culture (in a sample taken less than seven days previously)'.[@R26]

**Explanation**. Since a diagnostic accuracy study describes the behaviour of a test under particular circumstances, a report of the study must include a complete description of the criteria that were used to identify eligible participants. Eligibility criteria are usually related to the nature and stage of the target condition and the intended future use of the index test; they often include the signs, symptoms or previous test results that generate the suspicion about the target condition. Additional criteria can be used to exclude participants for reasons of safety, feasibility and ethical arguments.

Excluding patients with a specific condition or receiving a specific treatment known to adversely affect the way the test works can lead to inflated diagnostic accuracy estimates.[@R27] An example is the exclusion of patients using β blockers in studies evaluating the diagnostic accuracy of exercise ECG.

Some studies have one set of eligibility criteria for all study participants; these are sometimes referred to as single-gate or cohort studies. Other studies have one set of eligibility criteria for participants with the target condition, and (an)other set(s) of eligibility criteria for those without the target condition; these are called multiple-gate or case--control studies.[@R28]

*In the first example*, the eligibility criteria list presenting signs and symptoms, an age limit and exclusion based on specific conditions and treatments. Since the same set of eligibility criteria applies to all study participants, this is an example of a single-gate study.

*In the second example*, the authors used different eligibility criteria for participants with and without the target condition: one group consisted of patients with a confirmed diagnosis of *Clostridium difficile*, and one group consisted of healthy controls. This is an example of a multiple-gate study. Extreme contrasts between severe cases and healthy controls can lead to inflated estimates of accuracy.[@R6] [@R29]

Item 7. On what basis potentially eligible participants were identified (such as symptoms, results from previous tests, inclusion in registry)

**Example**. 'We reviewed our database of patients who underwent needle localization and surgical excision with digital breast tomosynthesis guidance from April 2011 through January 2013'.[@R23]

**Explanation**. The eligibility criteria specify who can participate in the study, but they do not describe how the study authors identified eligible participants. This can be performed in various ways.[@R30] A general practitioner may evaluate every patient for eligibility that he sees during office hours. Researchers can go through registries in an emergency department, to identify potentially eligible patients. In other studies, patients are only identified after having been subjected to the index test. Still other studies start with patients in whom the reference standard was performed. Many retrospective studies include participants based on searching hospital databases for patients that underwent the index test and the reference standard.[@R31]

Differences in methods for identifying eligible patients can affect the spectrum and prevalence of the target condition in the study group, as well as the range and relative frequency of alternative conditions in patients without the target condition.[@R32] These differences can influence the estimates of diagnostic accuracy.

*In the example*, participants were identified through searching a patient database and were included if they underwent the index test and the reference standard.

Item 8. Where and when potentially eligible participants were identified (setting, location and dates)

**Example**. 'The study was conducted at the Emergency Department of a university-affiliated children\'s hospital between January 21, 1996, and April 30, 1996'.[@R33]

**Explanation**. The results of a diagnostic accuracy study reflect the performance of a test in a particular clinical context and setting. A medical test may perform differently in a primary, secondary or tertiary care setting, for example. Authors should therefore report the actual setting in which the study was performed, as well as the exact locations: names of the participating centres, city and country. The spectrum of the target condition as well as the range of other conditions that occur in patients suspected of the target condition can vary across settings, depending on which referral mechanisms are in play.[@R34]

Since test procedures, referral mechanisms and the prevalence and severity of diseases can evolve over time, authors should also report the start and end dates of participant recruitment.

This information is essential for readers who want to evaluate the generalisability of the study findings, and their applicability to specific questions, for those who would like to use the evidence generated by the study to make informed healthcare decisions.

*In the example*, study setting and study dates were clearly defined.

Item 9. Whether participants formed a consecutive, random or convenience series

**Example**. 'All subjects were evaluated and screened for study eligibility by the first author (E.N.E.) prior to study entry. This was a convenience sample of children with pharyngitis; the subjects were enrolled when the first author was present in the emergency department'.[@R37]

**Explanation**. The included study participants may be either a consecutive series of all patients evaluated for eligibility at the study location and satisfying the inclusion criteria, or a subselection of these. A subselection can be purely random, produced by using a random numbers table, or less random, if patients are only enrolled on specific days or during specific office hours. In that case, included participants may not be considered a representative sample of the targeted population, and the generalisability of the study results may be jeopardised.[@R2] [@R29]

In the example, the authors explicitly described a convenience series where participants were enrolled based on their accessibility to the clinical investigator.

Item 10a. Index test, in sufficient detail to allow replication

Item 10b. Reference standard, in sufficient detail to allow replication

**Example**. 'An intravenous line was inserted in an antecubital vein and blood samples were collected into serum tubes before (baseline), immediately after, and 1.5 and 4.5 h after stress testing. Blood samples were put on ice, processed within 1 h of collection, and later stored at −80°C before analysis. The samples had been through 1 thaw--freeze cycle before cardiac troponin I (cTnI) analysis. We measured cTnI by a prototype hs assay (ARCHITECT *STAT* high-sensitivity troponin, Abbott Diagnostics) with the capture antibody detecting epitopes 24--40 and the detection antibody epitopes 41--49 of cTnI. The limit of detection (LoD) for the high sensitivity (hs) cTnI assay was recently reported by other groups to be 1.2 ng/L, the 99th percentile 16 ng/L, and the assay 10% coefficient of variation (CV) 3.0 ng/L. \[...\] Samples with concentrations below the range of the assays were assigned values of 1.2 \[...\] for cTnI. \[...\]'.[@R38]

**Explanation**. Differences in the execution of the index test or reference standard are a potential source of variation in diagnostic accuracy.[@R39] [@R40] Authors should therefore describe the methods for executing the index test and reference standard, in sufficient detail to allow other researchers to replicate the study, and to allow readers to assess (1) the feasibility of using the index test in their own setting, (2) the adequacy of the reference standard and (3) the applicability of the results to their clinical question.

The description should cover key elements of the test protocol, including details of: the preanalytical phase, for example, patient preparation such as fasting/feeding status prior to blood sampling, the handling of the sample prior to testing and its limitations (such as sample instability), or the anatomic site of measurement;the analytical phase, including materials and instruments and analytical procedures;the postanalytical phase, such as calculations of risk scores using analytical results and other variables.

Between-study variability in measures of test accuracy due to differences in test protocol has been documented for a number of tests, including the use of hyperventilation prior to exercise ECG and the use of tomography for exercise thallium scintigraphy.[@R27] [@R40]

The number, training and expertise of the persons executing and reading the index test and the reference standard may also be critical. Many studies have shown between-reader variability, especially in the field of imaging.[@R41] [@R42] The quality of reading has also been shown to be affected in cytology and microbiology by professional background, expertise and prior training to improve interpretation and to reduce interobserver variation.[@R43] Information about the amount of training of the persons in the study who read the index test can help readers to judge whether similar results are achievable in their own settings.

In some cases, a study depends on multiple reference standards. Patients with lesions on an imaging test under evaluation may, for example, undergo biopsy with a final diagnosis based on histology, whereas patients without lesions on the index test undergo clinical follow-up as reference standard. This could be a potential source of bias, so authors should specify which patient groups received which reference standard.[@R2] [@R3]

More specific guidance for specialised fields of testing, or certain types of tests, will be developed in future STARD extensions. Whenever available, these extensions will be made available on the STARD pages at the EQUATOR (Enhancing the QUAlity and Transparency Of health Research) website (<http://www.equator-network.org/>).

*In the example*, the authors described how blood samples were collected and processed in the laboratory. They also report analytical performance characteristics of the index test device, as obtained in previous studies.

Item 11. Rationale for choosing the reference standard (if alternatives exist)

**Example**. 'The MINI \[Mini International Neuropsychiatric Inventory\] was developed as a short and efficient diagnostic interview to be used in both research and clinical settings *(reference supporting this statement provided by the authors)*. It has good reliability and validity rates compared with other gold standard diagnostic interviews, such as the Structured Clinical Interview for DSM \[Diagnostic and Statistical Manual of Mental Disorders\] Disorders (SCID) and the Composite International Diagnostic Interview *(references supporting this statement provided by the authors)*'.[@R46]

**Explanation**. In diagnostic accuracy studies, the reference standard is used for establishing the presence or absence of the target condition in study participants. Several reference standards may be available to define the same target condition. In such cases, authors are invited to provide their rationale for selecting the specific reference standard from the available alternatives. This may depend on the intended use of the index test, the clinical relevance or practical and/or ethical reasons.

Alternative reference standards are not always in perfect agreement. Some reference standards are less accurate than others. In other cases, different reference standards reflect related but different manifestations or stages of the disease, as in confirmation by imaging (first reference standard) versus clinical events (second reference standard).

*In the example*, the authors selected the MINI, a structured diagnostic interview commonly used for psychiatric evaluations, as the reference standard for identifying depression and suicide risk in adults with epilepsy. As a rationale for their choice, they claimed that the MINI test was short to administer, efficient for clinical and research purposes, reliable and valid when compared with alternative diagnostic interviews.

Item 12a. Definition of and rationale for test positivity cut-offs or result categories of the index test, distinguishing prespecified from exploratory

Item 12b. Definition of and rationale for test positivity cut-offs or result categories of the reference standard, distinguishing prespecified from exploratory

**Example**. 'We also compared the sensitivity of the risk-model at the specificity that would correspond to using a fixed FIT \[fecal immunochemical test\] positivity threshold of 50 ng/ml. We used a threshold of 50 ng/ml because this was the anticipated cut-off for the Dutch screening programme at the time of the study'.[@R47]

**Explanation**. Test results in their original form can be dichotomous (positive vs negative), have multiple categories (as in high, intermediate or low risk) or be continuous (interval or ratio scale).

For tests with multiple categories, or continuous results, the outcomes from testing are often reclassified into positive (disease confirmed) and negative (disease excluded). This is performed by defining a threshold: the test positivity cut-off. Results that exceed the threshold would then be called positive index test results. In other studies, an ROC curve is derived, by calculating the sensitivity--specificity pairs for all possible cut-offs.

To evaluate the validity and applicability of these classifications, readers would like to know these positivity cut-offs or result categories, how they were determined and whether they were defined prior to the study or after collecting the data. Prespecified thresholds can be based on (1) previous studies, (2) cut-offs used in clinical practice, (3) thresholds recommended by clinical practice guidelines or (4) thresholds recommended by the manufacturer. If no such thresholds exist, the authors may be tempted to explore the accuracy for various thresholds after the data have been collected.

If the authors selected the positivity cut-off after performing the test, choosing the one that maximised test performance, there is an increased risk that the resulting accuracy estimates are overly optimistic, especially in small studies.[@R48] [@R49] Subsequent studies may fail to replicate the findings.[@R50] [@R51]

*In the example*, the authors stated the rationale for their selection of cut-offs.

Item 13a. Whether clinical information and reference standard results were available to the performers or readers of the index test

Item 13b. Whether clinical information and index test results were available to the assessors of the reference standard

**Example**. 'Images for each patient were reviewed by two fellowship-trained genitourinary radiologists with 12 and 8 years of experience, respectively, who were blinded to all patient information, including the final histopathologic diagnosis'.[@R52]

**Explanation**. Some medical tests, such as most forms of imaging, require human handling, interpretation and judgement. These actions may be influenced by the information that is available to the reader.[@R1] [@R53] [@R54] This can lead to artificially high agreement between tests, or between the index test and the reference standard.

If the reader of a test has access to information about signs, symptoms and previous test results, the reading may be influenced by this additional information, but this may still represent how the test is used in clinical practice.[@R2] The reverse may also apply, if the reader does not have enough information for a proper interpretation of the index test outcome. In that case, test performance may be affected downwards, and the study findings may have limited applicability. Either way, readers of the study report should know to which extent, such additional information was available to test readers and may have influenced their final judgement.

In other situations, the assessors of the reference standard may have had access to the index test results. In those cases, the final classification may be guided by the index test result, and the reported accuracy estimates for the index test will be too high.[@R1] [@R2] [@R27] Tests that require subjective interpretation are particularly susceptible to this bias.

Withholding information from the readers of the test is commonly referred to as 'blinding' or 'masking'. The point of this reporting item is not that blinding is desirable or undesirable, but, rather, that readers of the study report need information about blinding for the index test and the reference standard to be able to interpret the study findings.

*In the example*, the readers of unenhanced CT for differentiating between renal angiomyolipoma and renal cell carcinoma did not have access to clinical information, nor to the results of histopathology, the reference standard in this study.

Item 14. Methods for estimating or comparing measures of diagnostic accuracy

**Example**. 'Statistical tests of sensitivity and specificity were conducted by using the McNemar test for correlated proportions. All tests were two sided, testing the hypothesis that stereoscopic digital mammography performance differed from that of digital mammography. A p-value of 0.05 was considered as the threshold for significance'.[@R55]

**Explanation**. Multiple measures of diagnostic accuracy exist to describe the performance of a medical test, and their calculation from the collected data is not always straightforward.[@R56] Authors should report the methods used for calculating the measures that they considered appropriate for their study objectives.

Statistical techniques can be used to test specific hypotheses, following from the study\'s objectives. In single-test evaluations, authors may want to evaluate if the diagnostic accuracy of the tests exceeds a prespecified level (eg, sensitivity of at least 95%, see Item 4).

Diagnostic accuracy studies can also compare two or more index tests. In such comparisons, statistical hypothesis testing usually involves assessing the superiority of one test over another, or the non-inferiority.[@R57] For such comparisons, authors should indicate what measure they specified to make the comparison; these should match their study objectives, and the purpose and role of the index test relative to the clinical pathway. Examples are the relative sensitivity, the absolute gain in sensitivity and the relative diagnostic OR.[@R58]

*In the example*, the authors used McNemar\'s test statistic to evaluate whether the sensitivity and specificity of stereoscopic digital mammography differed from that of digital mammography in patients with elevated risk for breast cancer. In itself, the resulting p value is not a quantitative expression of the relative accuracy of the two investigated tests. Like any p value, it is influenced by the magnitude of the difference in effect and the sample size. In the example, the authors could have calculated the relative or absolute difference in sensitivity and specificity, including a 95% CI that takes into account the paired nature of the data.

Item 15. How indeterminate index test or reference standard results were handled

**Example**. 'Indeterminate results were considered false-positive or false-negative and incorporated into the final analysis. For example, an indeterminate result in a patient found to have appendicitis was considered to have had a negative test result'.[@R59]

**Explanation**. Indeterminate results refer to those that are neither positive or negative.[@R60] Such results can occur on the index test and the reference standard, and are a challenge when evaluating the performance of a diagnostic test.[@R60] The occurrence of indeterminate test results varies from test to test, but frequencies up to 40% have been reported.[@R62]

There are many underlying causes for indeterminate test results.[@R62] [@R63] A test may fail because of technical reasons or an insufficient sample, for example, in the absence of cells in a needle biopsy from a tumour.[@R43] [@R64] [@R65] Sometimes test results are not reported as just positive or negative, as in the case of ventilation--perfusion scanning in suspected pulmonary embolism, where the findings are classified in three categories: normal, high probability or inconclusive.[@R66]

In itself, the frequency of indeterminate test results is an important indicator of the feasibility of the test, and typically limits the overall clinical usefulness; therefore, authors are encouraged to always report the respective frequencies with reasons, as well as failures to complete the testing procedure. This applies to the index test and the reference standard.

Ignoring indeterminate test results can produce biased estimates of accuracy, if these results do not occur at random. Clinical practice may guide the decision on how to handle indeterminate results.

There are multiple ways for handling indeterminate test results in the analysis when estimating accuracy and expressing test performance.[@R63] They can be ignored altogether, be reported but not accounted for or handled as a separate test result category. Handling these results as a separate category may be useful when indeterminate results occur more often, for example, in those without the target condition than in those with the target condition. It is also possible to reclassify all such results: as false positives or false negatives, depending on the reference standard result ('worst-case scenario'), or as true positives and true negatives ('best-case scenario').

*In the example*, the authors explicitly chose a conservative approach by considering all indeterminate results from the index test as being false-negative (in those with the target condition) or false-positive (in all others), a strategy sometimes referred to as the 'worst-case scenario'.

Item 16. How missing data on the index test and reference standard were handled

**Example**. 'One vessel had missing FFR~CT~ and 2 had missing CT data. Missing data were handled by exclusion of these vessels as well as by the worst-case imputation'.[@R67]

**Explanation**. Missing data are common in any type of biomedical research. In diagnostic accuracy studies, they can occur for the index test and reference standard. There are several ways to deal with them when analysing the data.[@R68] Many researchers exclude participants without an observed test result. This is known as 'complete case' or 'available case' analysis. This may lead to a loss in precision and can introduce bias, especially if having a missing index test or reference standard result is related to having the target condition.

Participants with missing test results can be included in the analysis if missing results are imputed.[@R68] Another option is to assess the impact of missing test results on estimates of accuracy by considering different scenarios. For the index test, for example, in the 'worst-case scenario', all missing index test results are considered false-positive or false-negative depending on the reference standard result; in the 'best-case scenario', all missing index test results are considered true-positive or true-negative.

*In the example*, the authors explicitly reported how many cases with missing index test data they encountered and how they handled these data: they excluded them, but also applied a 'worst-case scenario'.

Item 17. Any analyses of variability in diagnostic accuracy, distinguishing prespecified from exploratory

**Example**. 'To assess the performance of urinary indices or their changes over the first 24 hours in distinguishing transient AKI \[acute kidney injury\] from persistent AKI, we plotted the receiver-operating characteristic curves for the proportion of true positives against the proportion of false positives, depending on the prediction rule used to classify patients as having persistent AKI. The same strategy was used to assess the performance of indices and their changes over time in two predefined patient subgroups; namely, patients who did not receive diuretic therapy and patients without sepsis'.[@R71]

**Explanation**. The relative proportion of false-positive or false-negative results of a diagnostic test may vary depending on patient characteristics, experience of readers, the setting and previous test results.[@R2] [@R3] Researchers may therefore want to explore possible sources of variability in test accuracy within their study. In such analyses, investigators typically assess differences in accuracy across subgroups of participants, readers or centres.

Post hoc analyses, performed after looking at the data, carry a high risk for spurious findings. The results are especially likely not to be confirmed by subsequent studies. Analyses that were prespecified in the protocol, before data were collected, have greater credibility.[@R72]

*In the example*, the authors reported that the accuracy of the urinary indices was evaluated in two subgroups that were explicitly prespecified.

Item 18. Intended sample size and how it was determined

**Example**. 'Study recruitment was guided by an expected 12% prevalence of adenomas 6 mm or larger in a screening cohort and a point estimate of 80% sensitivity for these target lesions. We planned to recruit approximately 600 participants to achieve margins of sampling error of approximately 8 percentage points for sensitivity. This sample would also allow 90% power to detect differences in sensitivity between computed tomographic colonography and optical colonoscopy of 18 percentage points or more'.[@R73]

**Explanation**. Performing sample size calculations when developing a diagnostic accuracy study may ensure that a sufficient amount of precision is reached. Sample size calculations also take into account the specific objectives and hypotheses of the study.

Readers may want to know how the sample size was determined, and whether the assumptions made in this calculation are in line with the scientific and clinical background, and the study objectives. Readers will also want to learn whether the study authors were successful in recruiting the targeted number of participants. Methods for performing sample size calculations in diagnostic research are widely available,[@R74] but such calculations are not always performed or provided in reports of diagnostic accuracy studies.[@R77] [@R78]

Many diagnostic accuracy studies are small; a systematic survey of studies published in 8 leading journals in 2002 found a median sample size of 118 participants (IQR 71--350).[@R77] Estimates of diagnostic accuracy from small studies tend to be imprecise, with wide CIs around them.

*In the example*, the authors reported in detail to achieve a desired level of precision for an expected sensitivity of 80%.

Results {#s3}
=======

Item 19. Flow of participants, using a diagram

**Example**. 'Between 1 June 2008 and 30 June 2011, 360 patients were assessed for initial eligibility and invited to participate. The figure shows the flow of patients through the study, along with the primary outcome of advanced colorectal neoplasia. Patients who were excluded (and reasons for this) or who withdrew from the study are noted. In total, 229 patients completed the study, a completion rate of 64%'.[@R79] (See [figure 1](#BMJOPEN2016012799F1){ref-type="fig"}.)

![Example of flow diagram from a study evaluating the accuracy of faecal immunochemical testing for diagnosis of advanced colorectal neoplasia (adapted from Collins *et al*,[@R79] with permission).](bmjopen2016012799f01){#BMJOPEN2016012799F1}

**Explanation**. Estimates of diagnostic accuracy may be biased if not all eligible participants undergo the index test and the desired reference standard.[@R80] This includes studies in which not all study participants undergo the reference standard, as well as studies where some of the participants receive a different reference standard.[@R70] Incomplete verification by the reference standard occurs in up to 26% of diagnostic studies; it is especially common when the reference standard is an invasive procedure.[@R84]

To allow the readers to appreciate the potential for bias, authors are invited to build a diagram to illustrate the flow of participants through the study. Such a diagram also illustrates the basic structure of the study. An example of a prototypical STARD flow diagram is presented in [figure 2](#BMJOPEN2016012799F2){ref-type="fig"}.

![STARD 2015 flow diagram.](bmjopen2016012799f02){#BMJOPEN2016012799F2}

By providing the exact number of participants at each stage of the study, including the number of true-positive, false-positive, true-negative and false-negative index test results, the diagram also helps identifying the correct denominator for calculating proportions such as sensitivity and specificity. The diagram should also specify the number of participants that were assessed for eligibility, the number of participants who did not receive either the index test and/or the reference standard and the reasons for that. This helps readers to judge the risk of bias, but also the feasibility of the evaluated testing strategy, and the applicability of the study findings.

*In the example*, the authors very briefly described the flow of participants, and referred to a flow diagram in which the number of participants and corresponding test results at each stage of the study were provided, as well as detailed reasons for excluding participants ([figure 1](#BMJOPEN2016012799F1){ref-type="fig"}).

Item 20. Baseline demographic and clinical characteristics of participants

**Example**. 'The median age of participants was 60 years (range 18--91), and 209 participants (54.7%) were female. The predominant presenting symptom was abdominal pain, followed by rectal bleeding and diarrhea, whereas fever and weight loss were less frequent. At physical examination, palpation elicited abdominal pain in almost half the patients, but palpable abdominal or rectal mass was found in only 13 individuals (Table X)'.[@R87] (See [table 3](#BMJOPEN2016012799TB3){ref-type="table"}.)

###### 

Example of baseline demographic and clinical characteristics of participants in a study evaluating the accuracy of point-of-care fecal tests for diagnosis of organic bowel disease (adapted from Kok *et al*,[@R87] with permission)

  Patient characteristics                             n (%)
  --------------------------------------------------- ------------------------------
  Geographic region of residency in the Netherlands   
   Central (Gelderse Vallei)                          257 (66.6)
   South (Oostelijke Mijnstreek)                      129 (33.4)
  Median age, years (range)                           60 (18--91)
  Women                                               211 (54.7)
  Presenting symptoms                                 
   Rectal blood loss                                  141 (37.7)
   Abdominal pain                                     267 (70.6)
   Median duration of abdominal pain (range)          150 days (1 day to 30 years)
   Persistent diarrhoea                               40 (16.9)
   Diarrhoea                                          131 (37.2)
   Fever                                              40 (11.0)
   Weight loss                                        62 (17.1)
   Bloating                                           195 (53.6)
   Constipation                                       169 (46.6)
  Physical examination                                
   Pain at palpation                                  117 (46.8)
   Palpable abdominal mass                            12 (3.0)
   Palpable rectal mass                               1 (0.3)

**Explanation**. The diagnostic accuracy of a test can depend on the demographic and clinical characteristics of the population in which it is applied.[@R2] [@R3] [@R88] These differences may reflect variability in the extent or severity of disease, which affects sensitivity, or in the alternative conditions that are able to generate false-positive findings, affecting specificity.[@R85]

An adequate description of the demographic and clinical characteristics of study participants allows the reader to judge whether the study can adequately address the study question, and whether the study findings apply to the reader\'s clinical question.

*In the example*, the authors presented the demographic and clinical characteristics of the study participants in a separate table, a commonly used, informative way of presenting key participant characteristics ([table 3](#BMJOPEN2016012799TB3){ref-type="table"}).

Item 21a. Distribution of severity of disease in those with the target condition

Item 21b. Distribution of alternative diagnoses in those without the target condition

**Example**. 'Of the 170 patients with coronary disease, one had left main disease, 53 had three vessel disease, 64 two vessel disease, and 52 single vessel disease. The mean ejection fraction of the patients with coronary disease was 64% (range 37--83). The other 52 men with symptoms had normal coronary arteries or no significant lesions at angiography'.[@R93]

**Explanation**. Most target conditions are not fixed states, either present or absent; many diseases cover a continuum, ranging from minute pathological changes to advanced clinical disease. Test sensitivity is often higher in studies in which more patients have advanced stages of the target condition, as these cases are often easier to identify by the index test.[@R28] [@R85] The type, spectrum and frequency of alternative diagnoses in those without the target condition may also influence test accuracy; typically, the healthier the patients without the target condition, the less frequently one would find false-positive results of the index test.[@R28]

An adequate description of the severity of disease in those with the target condition and of the alternative conditions in those without it allows the reader to judge both the validity of the study, relative to the study question and the applicability of the study findings to the reader\'s clinical question.

*In the example*, the authors investigated the accuracy of exercise tests for diagnosing coronary artery disease. They reported the distribution of severity of disease in terms of the number of vessels involved; the more vessels, the more severe the coronary artery disease would be. Sensitivity of test exercises was higher in those with more diseased vessels (39% for single vessel disease, 58% for two and 77% for three vessels).[@R91]

Item 22. Time interval and any clinical interventions between index test and reference standard

**Example**. 'The mean time between arthrometric examination and MR imaging was 38.2 days (range, 0--107 days)'.[@R94]

**Explanation**. Studies of diagnostic accuracy are essentially cross-sectional investigations. In most cases, one wants to know how well the index test classified patients in the same way as the reference standard, when both tests are performed in the same patients, at the same time.[@R30] When a delay occurs between the index test and the reference standard, the target condition and alternative conditions can change; conditions may worsen, or improve in the meanwhile, due to the natural course of the disease, or due to clinical interventions applied between the two tests. Such changes influence the agreement between the index test and the reference standard, which could lead to biased estimates of test performance.

The bias can be more severe if the delay differs systematically between test positives and test negatives, or between those with a high prior suspicion of having the target condition and those with a low suspicion.[@R1] [@R2]

When follow-up is used as the reference standard, readers will want to know how long the follow-up period was.

*In the example*, the authors reported the mean number of days, and a range, between the index test and the reference standard.

Item 23. Cross tabulation of the index test results (or their distribution) by the results of the reference standard

**Example**. 'Table X shows pain over speed bumps in relation to diagnosis of appendicitis'.[@R95] (See [table 4](#BMJOPEN2016012799TB4){ref-type="table"}.)

###### 

Example of contingency table from a study evaluating the accuracy of pain over speed bumps for diagnosis of appendicitis (adapted from Ashdown *et al*,[@R95] with permission)

             Appendicitis        
  ---------- -------------- ---- ----
  Positive   33             21   54
  Negative   1              9    10
  Total      34             30   64

**Explanation**. Research findings should be reproducible and verifiable by other scientists; this applies both to the testing procedures, to the conduct of the study and to the statistical analyses.

A cross tabulation of index test results against reference standard results facilitates recalculating measures of diagnostic accuracy. It also facilitates recalculating the proportion of study group participants with the target condition, which is useful as the sensitivity and specificity of a test may vary with disease prevalence.[@R32] [@R96] It also allows for performing alternative or additional analyses, such as meta-analysis.

Preferably, such tables should include actual numbers, not just percentages, because mistakes made by study authors in calculating estimates for sensitivity and specificity are not rare.

*In the example*, the authors provided a contingency table from which the number of true positives, false positives, false negatives and true negatives can be easily identified ([table 4](#BMJOPEN2016012799TB4){ref-type="table"}).

Item 24. Estimates of diagnostic accuracy and their precision (such as 95% CIs)

**Example**. 'Forty-six patients had pulmonary fibrosis at CT, and sensitivity and specificity of MR imaging in the identification of pulmonary fibrosis were 89% (95% CI 77%, 96%) and 91% (95% CI 76%, 98%), respectively, with positive and negative predictive values of 93% (95% CI 82%, 99%) and 86% (95% CI 70%, 95%), respectively'.[@R97]

**Explanation**. Diagnostic accuracy studies never determine a test\'s 'true' sensitivity and specificity; at best, the data collected in the study can be used to calculate valid estimates of sensitivity and specificity. The smaller the number of study participants, the less precise these estimates will be.[@R98]

The most frequently used expression of imprecision is to report not just the estimates---sometimes referred to as point estimates---but also 95% CIs around the estimates. Results from studies with imprecise estimates of accuracy should be interpreted with caution, as overoptimism lurks.[@R22]

*In the example*, where MRI is the index test and CT the reference standard, the authors reported point estimates and 95% CIs around them, for sensitivity, specificity and positive and negative predictive value.

Item 25. Any adverse events from performing the index test or the reference standard

**Example**. 'No significant adverse events occurred as a result of colonoscopy. Four (2%) patients had minor bleeding in association with polypectomy that was controlled endoscopically. Other minor adverse events are noted in the appendix'.[@R79]

**Explanation**. Not all medical tests are equally safe, and in this, they do not differ from many other medical interventions.[@R99] [@R100] The testing procedure can lead to complications, such as perforations with endoscopy, contrast allergic reactions in CT imaging or claustrophobia with MRI scanning.

Measuring and reporting of adverse events in studies of diagnostic accuracy will provide additional information to clinicians, who may be reluctant to use them if they produce severe or frequent adverse events. Actual application of a test in clinical practice will not just be guided by the test\'s accuracy, but by several other dimensions as well, including feasibility and safety. This also applies to the reference standard.

*In the example*, the authors distinguished between 'significant' and 'minor' adverse events, and explicitly reported how often these were observed.

Discussion {#s4}
==========

Item 26. Study limitations, including sources of potential bias, statistical uncertainty and generalisability

**Example.** 'This study had limitations. First, not all patients who underwent CT colonography (CTC) were assessed by the reference standard methods. \[...\] However, considering that the 41 patients who were eligible but did not undergo the reference standard procedures had negative or only mildly positive CTC findings, excluding them from the analysis of CTC diagnostic performance may have slightly overestimated the sensitivity of CTC (ie, partial verification bias). Second, there was a long time interval between CTC and the reference methods in some patients, predominately those with negative CTC findings. \[...\] If anything, the prolonged interval would presumably slightly underestimate the sensitivity and NPV of CTC for non-cancerous lesions, since some "missed" lesions could have conceivably developed or increased in size since the time of CTC'.[@R101]

**Explanation**. Like other clinical trials and studies, diagnostic accuracy studies are at risk of bias; they can generate estimates of the test\'s accuracy that do not reflect the true performance of the test, due to flaws or deficiencies in study design and analysis.[@R1] [@R2] In addition, imprecise accuracy estimates, with wide CIs, should be interpreted with caution. Because of differences in design, participants and procedures, the findings generated by one particular diagnostic accuracy study may not be obtained in other conditions; their generalisability may be limited.[@R102]

In the Discussion section, authors should critically reflect on the validity of their findings, address potential limitations and elaborate on why study findings may or may not be generalisable. As bias can come down to overestimation or underestimation of the accuracy of the index test under investigation, authors should discuss the direction of potential bias, along with its likely magnitude. Readers are then informed of the likelihood that the limitations jeopardise the study\'s results and conclusions (see also Item 27).[@R103]

Some journals explicitly encourage authors to report on study limitations, but many are not specific about which elements should be addressed.[@R104] For diagnostic accuracy studies, we highly recommend that at least potential sources of bias are discussed, as well as imprecision, and concerns related to the selection of patients and the setting in which the study was performed.

*In the example*, the authors identified two potential sources of bias that are common in diagnostic accuracy studies: not all test results were verified by the reference standard, and there was a time interval between index test and reference standard, allowing the target condition to change. They also discussed the magnitude of this potential bias, and the direction: whether this may have led to overestimations or underestimations of test accuracy.

Item 27. Implications for practice, including the intended use and clinical role of the index test

**Example**. 'A Wells score of ≤4 combined with a negative point of care D-dimer test result ruled out pulmonary embolism in 4--5 of 10 patients, with a failure rate of less than 2%, which is considered safe by most published consensus statements. Such a rule-out strategy makes it possible for primary care doctors to safely exclude pulmonary embolism in a large proportion of patients suspected of having the condition, thereby reducing the costs and burden to the patient (for example, reducing the risk of contrast nephropathy associated with spiral computed tomography) associated with an unnecessary referral to secondary care'.[@R25]

**Explanation**. To make the study findings relevant for practice, authors of diagnostic accuracy studies should elaborate on the consequences of their findings, taking into account the intended use (the purpose of testing) and clinical role of the test (how will the test be positioned in the existing clinical pathway).

A test can be proposed for diagnostic purposes, for susceptibility, screening, risk stratification, staging, prediction, prognosis, treatment selection, monitoring, surveillance or other purposes. The clinical role of the test reflects its positioning relative to existing tests for the same purpose, within the same clinical setting: triage, add-on or replacement.[@R19] [@R105] The intended use and the clinical role of the index test should have been described in the introduction of the paper (Item 3).

The intended use and the proposed role will guide the desired magnitude of the measures of diagnostic accuracy. For ruling-out disease with an inexpensive triage test, for example, high sensitivity is required, and less-than-perfect specificity may be acceptable. If the test is supposed to rule-in disease, specificity may become much more important.[@R106]

In the Discussion section, authors should elaborate on whether or not the accuracy estimates are sufficient for considering the test to be 'fit for purpose'.

*In the example*, the authors concluded that the combination of a Wells score ≤4 and a negative point-of-care D-dimer result could reliably rule-out pulmonary embolism in a large proportion of patients seen in primary care.

Other information {#s4a}
-----------------

Item 28. Registration number and name of registry

**Example**. 'The study was registered at <http://www.clinicaltrials.org> (NCT00916864)'.[@R107]

**Explanation**. Registering study protocols before their initiation in a clinical trial registry, such as ClinicalTrials.gov or one of the WHO Primary Registries, ensures that existence of the studies can be identified.[@R108] This has many advantages, including avoiding overlapping or redundant studies, and allowing colleagues and potential participants to contact the study coordinators.

Additional benefits of study registration are the prospective definition of study objectives, outcome measures, eligibility criteria and data to be collected, allowing editors, reviewers and readers to identify deviations in the final study report. Trial registration also allows reviewers to identify studies that have been completed but were not yet reported.

Many journals require registration of clinical trials. A low but increasing number of diagnostic accuracy studies are also being registered. In a recent evaluation of 351 test accuracy studies published in high-impact journals in 2012, 15% had been registered.[@R113]

Including a registration number in the study report facilitates identification of the trial in the corresponding registry. It can also be regarded as a sign of quality, if the trial was registered before its initiation.

*In the example*, the authors reported that the study was registered at ClinicalTrials.gov. The registration number was also provided, so that the registered record could be easily retrieved.

Item 29. Where the full study protocol can be accessed

**Example**. 'The design and rationale of the OPTIMAP study have been previously published in more detail \[with reference to study protocol\]'.[@R114]

**Explanation**. Full study protocols typically contain additional methodological information that is not provided in the final study report, because of word limits, or because it has been reported elsewhere. This additional information can be helpful for those who want to thoroughly appraise the validity of the study, for researchers who want to replicate the study and for practitioners who want to implement the testing procedures.

An increasing number of researchers share their original study protocol, often before enrolment of the first participant in the study. They may do so by publishing the protocol in a scientific journal, at an institutional or sponsor website, or as supplementary material on the journal website, to accompany the study report.

If the protocol has been published or posted online, authors should provide a reference or a link. If the study protocol has not been published, authors should state from whom it can be obtained.[@R115]

*In the example*, the authors provided a reference to the full protocol, which had been published previously.

Item 30. Sources of funding and other support; role of funders

**Example**. 'Funding, in the form of the extra diagnostic reagents and equipment needed for the study, was provided by Gen-Probe. The funders had no role in the initiation or design of the study, collection of samples, analysis, interpretation of data, writing of the paper, or the submission for publication. The study and researchers are independent of the funders, Gen-Probe'.[@R116]

**Explanation**. Sponsorship of a study by a pharmaceutical company has been shown to be associated with results favouring the interests of that sponsor.[@R117] Unfortunately, sponsorship is often not disclosed in scientific articles, making it difficult to assess this potential bias. Sponsorship can consist of direct funding of the study, or of the provision of essential study materials, such as test devices.

The role of the sponsor, including the degree to which that sponsor was involved in the study, varies. A sponsor could, for example, be involved in the design of the study, but also in the conduct, analysis, reporting and decision to publish. Authors are encouraged to be explicit about sources of funding as well as the sponsors role(s) in the study, as this transparency helps readers to appreciate the level of independency of the researchers.

*In the example*, the authors were explicit about the contribution from the sponsor, and their independence in each phase of the study.

The authors thank the STARD Group for helping us in identifying essential items for reporting diagnostic accuracy studies.
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